

# Emilie Lanoy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4688754/publications.pdf>

Version: 2024-02-01

67  
papers

6,189  
citations

126907

33  
h-index

114465

63  
g-index

69  
all docs

69  
docs citations

69  
times ranked

10037  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry. <i>Gynecologic Oncology</i> , 2021, 160, 77-82.	1.4	2
2	Intratumoral Immunotherapy: From Trial Design to Clinical Practice. <i>Clinical Cancer Research</i> , 2021, 27, 665-679.	7.0	69
3	Trend of antibiotic consumption and its association with influenza-like illnesses in France between 2004 and 2018. <i>European Journal of Public Health</i> , 2021, 31, 1137-1143.	0.3	3
4	Integrating expertâ€™s knowledge constraint of time dependent exposures in structure learning for Bayesian networks. <i>Artificial Intelligence in Medicine</i> , 2020, 107, 101874.	6.5	6
5	No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer. <i>BMC Cancer</i> , 2019, 19, 847.	2.6	8
6	One or Two Immune Checkpoint Inhibitors?. <i>Cancer Cell</i> , 2019, 36, 579-581.	16.8	11
7	Long-Term Survival in Patients Responding to Antiâ€™PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. <i>Clinical Cancer Research</i> , 2019, 25, 946-956.	7.0	96
8	Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases. <i>Melanoma Research</i> , 2018, 28, 111-119.	1.2	51
9	Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. <i>European Journal of Cancer</i> , 2018, 91, 21-29.	2.8	222
10	What's next in using CT scans to better understand cachexia?. <i>Current Opinion in Supportive and Palliative Care</i> , 2018, 12, 427-433.	1.3	4
11	Estimating causal effects of time-dependent exposures on a binary endpoint in a high-dimensional setting. <i>BMC Medical Research Methodology</i> , 2018, 18, 67.	3.1	2
12	Statistical approaches for evaluating body composition markers in clinical cancer research. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 311-318.	2.4	8
13	Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study. <i>Supportive Care in Cancer</i> , 2017, 25, 3365-3373.	2.2	13
14	Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. <i>Annals of Oncology</i> , 2017, 28, 1368-1379.	1.2	908
15	In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?. <i>European Journal of Cancer</i> , 2017, 87, 65-74.	2.8	19
16	Patient-reported tolerability of adverse events in phase 1 trials. <i>ESMO Open</i> , 2017, 2, e000148.	4.5	20
17	A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents. <i>Cancer Research</i> , 2017, 77, 557-565.	0.9	10
18	A dose escalation phase 1 study of radiotherapy (RT) in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody ipilimumab in patients (pts) with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9549-9549.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3. <i>Oncotarget</i> , 2017, 8, 108786-108801.	1.8	22
20	Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients. <i>Oncotarget</i> , 2016, 7, 25549-25557.	1.8	15
21	A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials. <i>PLoS ONE</i> , 2016, 11, e0154895.	2.5	10
22	Patients aged over 75 years enrolled in Phase I clinical trials: the <sc>G</sc>ustave <sc>R</sc>oussy experience. <i>International Journal of Cancer</i> , 2016, 138, 875-880.	5.1	5
23	Impact of dermatologic adverse events induced by targeted therapies on quality of life. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 101, 158-168.	4.4	12
24	Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials. <i>International Journal of Cardiology</i> , 2016, 214, 364-369.	1.7	0
25	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 473-486.	27.6	831
26	Uncovering Professional Attitudes Toward Treatment of Rare Carcinomas of the Breast: An International Practice e-Survey Involving 32 Countries. <i>Breast Journal</i> , 2016, 22, 96-100.	1.0	0
27	Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 3891-3898.	1.5	63
28	Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 395-401.	1.3	274
29	Impact of Skin Toxicities Associated with Targeted Cancer Therapies on Body Image: A Prospective Study. <i>Clinical Drug Investigation</i> , 2016, 36, 235-242.	2.2	4
30	Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. <i>Annals of Oncology</i> , 2016, 27, 214-224.	1.2	86
31	Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. <i>JAMA Dermatology</i> , 2016, 152, 45.	4.1	539
32	Nail toxicities induced by systemic anticancer treatments. <i>Lancet Oncology</i> , The, 2015, 16, e181-e189.	10.7	139
33	A randomized, open label, multicenter comparative phase II trial of ipilimumab after isolated limb perfusion (ILP), versus ILP alone in patients with in-transit metastases melanoma stage IIIB and IIIC.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20107-e20107.	1.6	0
34	Profiles of screen-failures in phase 1 clinical trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17518-e17518.	1.6	0
35	Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 279-288.	2.4	16
36	Statistical methods applied to omics data. <i>Current Opinion in Oncology</i> , 2014, 26, 576-583.	2.4	4

#	ARTICLE	IF	CITATIONS
37	Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. <i>Neurology</i> , 2014, 83, 134-141.	1.1	112
38	Weight, skeletal muscle mass, and adipose tissue loss during lung cancer patients' treatment.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20627-e20627.	1.6	0
39	Missed opportunities for HIV testing in newly-HIV-diagnosed patients, a cross sectional study. <i>BMC Infectious Diseases</i> , 2013, 13, 200.	2.9	75
40	Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. <i>Annals of Oncology</i> , 2013, 24, 1697-1703.	1.2	280
41	Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2013, 7, 383-389.	1.3	116
42	Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. <i>Cancer</i> , 2013, 119, 3377-3384.	4.1	170
43	Lack of regression of anal squamous intraepithelial lesions despite immune restoration under cART. <i>Aids</i> , 2013, 27, 401-406.	2.2	21
44	Effect of Alendronate on HIV-Associated Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled, 96-Week Trial (ANRS 120). <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 972-980.	1.1	36
45	Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. <i>BJU International</i> , 2012, 110, 1747-1753.	2.5	60
46	Breast cancer among HIV infected individuals from the ONCOVIH study, in France: Therapeutic implications. <i>European Journal of Cancer</i> , 2012, 48, 3335-3341.	2.8	22
47	High-dose ifosfamide (HDI) in metastatic synovial sarcoma: The Institut Gustave Roussy experience.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10044-10044.	1.6	4
48	Tumor burden as an independent prognostic factor in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 397-397.	1.6	11
49	Prognostic role of body composition parameters in renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4621-4621.	1.6	0
50	HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. <i>Blood</i> , 2011, 118, 44-49.	1.4	62
51	When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries. <i>Annals of Internal Medicine</i> , 2011, 154, 509.	3.9	205
52	The spectrum of malignancies in HIV-infected patients in 2006 in France: The ONCOVIH study. <i>International Journal of Cancer</i> , 2011, 129, 467-475.	5.1	77
53	Survival after neuroAIDS. <i>Neurology</i> , 2011, 76, 644-651.	1.1	37
54	The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. <i>Aids</i> , 2010, 24, 123-137.	2.2	360

#	ARTICLE	IF	CITATIONS
55	When to Start Treatment? A Systematic Approach to the Comparison of Dynamic Regimes Using Observational Data. <i>International Journal of Biostatistics</i> , 2010, 6, Article 18.	0.7	160
56	Skin cancers associated with HIV infection and solid-organ transplantation among elderly adults. <i>International Journal of Cancer</i> , 2010, 126, 1724-1731.	5.1	102
57	Skin cancers associated with autoimmune conditions among elderly adults. <i>British Journal of Cancer</i> , 2010, 103, 112-114.	6.4	52
58	Observation plans in longitudinal studies with time-varying treatments. <i>Statistical Methods in Medical Research</i> , 2009, 18, 27-52.	1.5	73
59	How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortality 2000 survey and death certificates. <i>HIV Medicine</i> , 2009, 10, 236-245.	2.2	24
60	Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States. <i>Aids</i> , 2009, 23, 385-393.	2.2	103
61	Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. <i>Aids</i> , 2009, 23, 2199-2208.	2.2	40
62	Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. <i>HIV Medicine</i> , 2008, 9, 246-256.	2.2	58
63	Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipodystrophy: results from the 96-week randomized ANRS 108 NoNuke Trial. <i>HIV Medicine</i> , 2008, 9, 625-635.	2.2	21
64	Prothrombotic markers and early spontaneous recanalization in ST-segment elevation myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2007, 98, 420-426.	3.4	33
65	Frequency, determinants and consequences of delayed access to care for HIV infection in France. <i>Antiviral Therapy</i> , 2007, 12, 89-96.	1.0	89
66	Predictors identified for losses to follow-up among HIV-seropositive patients. <i>Journal of Clinical Epidemiology</i> , 2006, 59, 829-829.	5.0	85
67	Comparison of Dynamic Treatment Regimes via Inverse Probability Weighting. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 98, 237-242.	2.5	210